The DOI matches its Crossref record; the references it cites are not checked yet.
Gene Expression Profiling and Genetic Markers in Glioblastoma Survival
Published version of a preprint
Abstract
Despite the strikingly grave prognosis for older patients with glioblastomas, significant variability in patient outcome is experienced. To explore the potential for developing improved prognostic capabilities based on the elucidation of potential biological relationships, we did analyses of genes commonly mutated, amplified, or deleted in glioblastomas and DNA microarray gene expression data from tumors of glioblastoma patients of age >50 for whom survival is known. No prognostic significance was associated with genetic changes in epidermal growth factor receptor (amplified in 17 of 41 patients), TP53 (mutated in 11 of 41 patients), p16INK4A (deleted in 15 of 33 patients), or phosphatase and tensin homologue (mutated in 15 of 41 patients). Statistical analysis of the gene expression data in connection with survival involved exploration of regression models on small subsets of genes, based on computational search over multiple regression models with cross-validation to assess predictive validity. The analysis generated a set of regression models that, when weighted and combined according to posterior probabilities implied by the statistical analysis, identify patterns in expression of a small subset of genes that are associated with survival and have value in assessing survival risks. The dominant genes across such multiple regression models involve three key genes-SPARC (Osteonectin), Doublecortex, and Semaphorin3B-which play key roles in cellular migration processes. Additional analysis, based on statistical graphical association models constructed using similar computational analysis methods, reveals other genes which support the view that multiple mediators of tumor invasion may be important prognostic factor in glioblastomas in older patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MDM2 amplifications have not been shown to correlate with glioblastoma survival and/or prognosis.
“MDM2 amplifications have not been shown to correlate with GBM survival and/or prognosis [27,32,33,34].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [33]
CDKN2A/ARF loss has not been shown to correlate with glioblastoma prognosis and/or survival.
“CDKN2A/ARF loss has not been shown to correlate with GBM prognosis and/or survival [27,32,33,34].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [33]
The mutational status of TP53 and its pathway elements ARF-MDM2/4 has not been correlated with survival in glioblastoma, despite the high mutation frequency.
“Although mut-p53 has been correlated to poorer prognosis in breast and other cancers [32], the mutational status of TP53 and its various pathway elements (ARF-MDM2/4) has not been correlated with survival in GBM, despite the high mutation frequency [27,32,33,34].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [33]
Citations
The citation lists haven’t been fetched yet
References 50 · Cited by 316
Metadata
- Authors
- Rich, J. N., Hans, C., Jones, B., Iversen, E. S., McLendon, R. E., Rasheed, B. K. A., Dobra, A., Dressman, H. K., Bigner, D. D., Nevins, J. R., & West, M.
- Affiliations
- Duke University (US)
- Massey University (NZ)
- Duke Medical Center (US)
- ORCID
- Venue
- Cancer Research
- Published
- 2005-05-15
- Volume
- 65
- Issue
- 10
- Pages
- 4051-4058
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2102000647
- Cited by
- 316
- References
- 50
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 10 · 2022: 7 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 12 · 2017: 8 · 2016: 9 · 2015: 6 · 2014: 16 · 2013: 21 · 2012: 27
- FWCI
- 13.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (K02NS047409, NS047409)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- glioblastoma, survival prediction, gene expression profiling, prognostic factors, elderly patients, TP53 mutation, PTEN mutation, SPARC, doublecortin, tumor invasion, cell migration, multiple regression model
- MeSH terms
- Doublecortin Domain Proteins, Aged, Brain Neoplasms, Female, Genetic Markers, Glioblastoma, Humans, Male, Membrane Glycoproteins, Microtubule-Associated Proteins, Middle Aged, Neuropeptides, Phosphoric Monoester Hydrolases, Reproducibility of Results, Osteonectin, Survival Rate, Tumor Suppressor Protein p53, Loss of Heterozygosity, Cyclin-Dependent Kinase Inhibitor p16, Gene Expression Profiling, Tumor Suppressor Proteins, Semaphorins, PTEN Phosphohydrolase, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review